Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Dec 07, 2020 12:39am
171 Views
Post# 32047686

RE:RE:RE:Hahaha... Rudy's got it

RE:RE:RE:Hahaha... Rudy's got it
Bunge wrote:
ScienceFirst wrote:

Just like Trump, he was also promoting HCQ.  And both, him and Trump, were taking HCQ before they caught it!  lollll

The same Gugliani that turned himself into ridicule in courts regarding the "electoral fraud" and lost all his cases, in front of judges named by Trump!  Don't you have to be a loser?

This Monday, Rudy Giuliani interviewed a woman alleged to be his mistress where they praised the benefits of the antimalarial drug hydroxychloroquine as a cure for coronavirus.

The two claimed that hydroxychloroquine was safe and effective in the fight against coronavirus.

“We spent some time looking at all the studies available, and there’s many available… there’s a pretty good study from France but also studies in Italy, Turkey and China, a very comprehensive study from Brazil that I liked…and they concluded that hydroxychloroqine, or as its referred to in the laboratory that HCQ, that HCQ is over 90 percent effective,” Ryan said.

According to a D.C. insider, it’s “pretty sad to see Rudy’s decline from ‘America’s mayor’ to hawking snake oil cures on a radio show that no one listens to.”

“At this rate, he’s going to be touting drinking bleach as a coronavirus cure on late-night infomercials before too long,” the insider added.

 



Oh Benny.

 

November 25, 2020 - A peer-reviewed study measuring the effectiveness of a controversial drug cocktail that includes hydroxychloroquine concluded that the treatment lowered hospitalizations and mortality rates of coronavirus patients. 

The study, set to be published in the International Journal of Antimicrobial Agents in December, determined that “Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.”

A total of 141 patients diagnosed with the coronavirus were treated with the three-drug cocktail over a period of five days and compared to a control group of 377 people who tested positive for the virus but were not given the treatment. 

The study found that “the odds of hospitalisation of treated patients was 84% less than in the untreated patients,” and only one patient died from the group being treated with the drugs compared to 13 deaths in the untreated group.




 


 

Hi Bunge, that's encouraging news.  Sometimes simple is simply better.  Perhaps you're already aware of this, but there's also an outpatient clinical trial that's ongoing at St. Francis Hospital, NY which is looking at the above drug cocktail.  They'll hopefully report results first half of next year.

Looks like this novel virus may be hanging around a while, so hopefully we see some Covid progress being made in our joint effort with U of M.  Having read the U of M bios, it seems Theralase has joined an excellent team of scientists.  

The recently reported Covid-19 vaccine efficacies from Moderna & Pfizer are impressive at ~95%, especially when your typical influenza vaccine is around 40-50%.  But even if there's little room for improvement on the Covid vaccine front, the world is still in need of much more targeted & effective therapeutics.  This is where I think Theralase has an even larger window of opportunity imo.  The competition in the Covid vaccine market will continue to be brutal & margins will be relatively low, which is typical of the vaccine manufacturing sector.  Imo, the greatest need (& real money) will be in therapeutics & I hope that is where Theralase can make some noise.

<< Previous
Bullboard Posts
Next >>